CeNeS Pharmaceuticals PLC: Successful Phase III Results Announced On Lead Product M6G
Published: Feb 20, 2007
CAMBRIDGE, UK -- (MARKET WIRE) -- February 20, 2007 -- CeNeS Pharmaceuticals plc (AIM: CEN), the Cambridge based biopharmaceutical company today announces preliminary results of the pivotal Phase III trial (M6G022) of M6G (morphine-6-glucuronide) in over 500 patients with post-operative pain. This study is the largest carried out to date with M6G and has delivered very strong results. M6G shows benefits over morphine in the management of post operative patients. M6G022 demonstrates the unique product profile of M6G with equal analgesia to morphine but with reduced nausea and vomiting.